LabStyle Innovations, the developer of the Dario™ smartphone-based diabetes medical device and data management system, announced that Prof. Itamar Raz, M.D., has been appointed to the Board of Directors, and he will serve on the Compensation Committee of the board. The company confirmed that Mr. Raz will continue to lead LabStyle’s Scientific Advisory Committee. The announcement was made from the American Diabetes Association’s 73rd Scientific Sessions, which is underway at the McCormick Place Convention Center in Chicago.
A world-renowned leader in diabetes treatment and research, Dr. Raz is an advisor to leading companies in the field. Currently serving as a professor of internal medicine at Hadassah University Medical Center in Israel, Dr. Raz is also the head of the Israel National Council of Diabetes of the Israel Ministry of Health, which is responsible for formulating national policies, the President of D-Cure, a diabetes not-for-profit organization, and the head of the Israel Diabetes Research Group. Dr. Raz also serves as a member of Advisory Boards of diabetes leaders Novo Nordisk (NVO), AstraZeneca/Bristol-Myers Squibb (NYSE: AZN / NYSE: BMY), Sanofi (SNY), Merck Sharp & Dohme (NYSE: MRK), and Eli Lilly (LLY).
“Dr. Raz strengthens our Board of Directors with his deep expertise in diabetes as a researcher, professor and tireless advocate for better treatment,” stated Dr. Oren Fuerst, LabStyle’s Chairman and Chief Executive Officer. “He is highly visible and well regarded in the diabetes community worldwide, and will be a valuable asset to our company as we seek to bring the many benefits of Dario to diabetics around the world.”
Commenting on his appointment, Dr. Raz added, “New tools and treatments for diabetics will help to contain the devastating impact of the growing diabetes epidemic. Information is the first step in improving outcomes. Dario is an innovative device and data-management system that I believe will catalyze more frequent testing due to its all-in-one design, while its many features, including the ability to share data in real-time with caregivers, will enable personalized care. In addition web-based social interactions between patients catalyzed by Dario create the potential for significant benefits through greater patient compliance.”
Dr. Raz is currently leading several international and clinical studies involving prevention and treatment of type 1 diabetes at Hadassah Hebrew University Hospital. With over 190 publications to his credit, Dr. Raz has published extensively on diabetes and also serves as a member of several medical editorial boards. Dr. Raz has organized several international meetings focused on diabetes, the largest being CODHy – Controversies in Obesity, Diabetes, and Hypertension.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
